A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

NCT04868708 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

BIOLOGICAL: AK104
BIOLOGICAL: Bevacizumab
DRUG: Paclitaxel
DRUG: Cisplatin or Carboplatin

Sponsor

Akeso